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The immunogenicity of a polyvalent HIV-1 vaccine comprised of Env antigens from primary R5 isolates was evaluated in rhesus macaques.
DNA vaccines encoding four Env antigens from multiple HIV-1 subtypes and HIV-1 Gag antigen from a single subtype elicited a persistent level
of binding antibodies to gp120 from multiple HIV-1 isolates that were markedly enhanced following boosting with homologous gp120 proteins in
QS-21 adjuvant irrespective of the route of DNA immunization. These sera neutralized homologous and, to a lesser degree, heterologous HIV-1
isolates. Four of the six immunized animals were completely protected following rectal challenge with a SHIV encoding Env from HIV-1Ba-L,
whereas the virus load was reduced in the remaining animals compared to naïve controls. Hence priming with DNA encoding Env antigens from
multiple HIV-1 clades followed by boosting with homologous Env proteins elicits anti-HIV-1 immune responses capable of protecting macaques
against mucosal transmission of R5 tropic SHIV isolate.
© 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1 Vaccine; Neutralizing antibody; R5 SHIV; Mucosal transmission; Nonhuman primatesIntroduction
Despite an intensive global effort to control human
immunodeficiency virus type 1 (HIV-1) infection, more than
40 million people are infected globally, and it is estimated
that nearly 16,000 people are newly infected with the virus
daily. A highly active anti-retroviral therapy (HAART) has
been proven to be effective in controlling viral load in
infected individuals (Mocroft et al., 2003a). However, such⁎ Corresponding author. Fax: +1 301 468 9466.
E-mail address: Ranajit.Pal@ablinc.com (R. Pal).
0042-6822/$ - see front matter © 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.12.029therapies are expensive, cause serious side effects, and may
eventually lead to viral resistance (Fatkenheuer et al., 1997;
Mocroft et al., 2003b; Shelburne et al., 2005; Wit et al.,
1999). A prophylactic vaccine, effective in various regions of
the world, is desperately needed to thwart this pandemic. This
is especially true in developing nations where the infection is
spreading at an alarming rate and opportunities for drug
interventions are limited. Development of a broadly effective
vaccine has become a major challenge since specific subtypes
of HIV-1 are prevalent in various regions of the world and
often these subtypes are quite divergent (Letvin et al., 2002;
Nabel, 2001; Nabel et al., 2002).
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cellular immunity are inversely correlated with HIV-1 disease
progression in humans (Pantaleo and Fauci, 1996; Soudeyns
and Pantaleo, 1999), it was proposed that a prophylactic HIV-1
vaccine should elicit both humoral and cell-mediated immune
(CMI) responses for the containment of viral infection (Letvin,
1998, 2005; Mascola and Nabel, 2001). Although DNA
vaccines prime both humoral and cellular immune responses,
the levels are often quite low in nonhuman primates or humans
(Calarota and Weiner, 2004; Estcourt et al., 2004; Robinson,
1999). Hence, efforts have been directed towards boosting such
immune responses by combining DNA vaccines with different
vaccination modalities in the boosting phase. Indeed, several
preclinical studies have clearly demonstrated significant control
of plasma viremia against pathogenic SHIV challenge using
prime-boost vaccines, which contained a DNA prime compo-
nent, and the boosting agents are often live vector-based
vaccines directed primarily at eliciting CMI responses (Amara
et al., 2001; Barouch et al., 2000; Doria-Rose et al., 2003;
Shiver et al., 2002).
Passive immunization experiments have demonstrated the
protective effects of HIV-1 Env-specific neutralizing antibodies
against SHIV transmission (Gauduin et al., 1997; Lewis et al.,
1993; Mascola et al., 1999, 2000; Shibata et al., 1999).
Therefore, several vaccines have been designed to use Env-
based immunogens in an effort to protect macaques from SHIV
and SIV challenge (Amara et al., 2002; Letvin et al., 2004). It
was demonstrated previously that anti-Env antibody responses
were broadened significantly following immunization with a
cocktail of Env proteins in vaccinia-primed macaques (Cho et
al., 2001). Polyvalent Env vaccines representing Env antigens
from different subtypes of HIV-1, which are currently
circulating globally, have not been extensively evaluated.
Further, it is not clear whether the number of immunogens in
a polyvalent Env vaccine influences the overall immune
response of the vaccine. A recent study has demonstrated that
immunization of macaques with DNA prime/recombinant
adenovirus boost vaccines encoding Env from clades A, B,
and C was able to elicit broad Env-specific T lymphocyte and
antibody responses (Seaman et al., 2005).Fig. 1. Immunization schedule. Six macaques were divided into two groups. Three an
ID route. All animals received protein immunization intramuscularly. Animals in both
of vaccination.Generally, DNAvaccines are effective in stimulating cellular
immune responses (Amara et al., 2001; Barouch et al., 2000;
Robinson, 1999), while subunit proteins are more effective in
eliciting antibody responses (Clements-Mann et al., 1998; Earl
et al., 2001, 2002; Graham et al., 1993). Env vaccines in the form
of subunit Env protein have been shown to be safe and effective
in eliciting antibody response in the immunized hosts. It has
been previously demonstrated that high-titered Env-specific
antibody responses could be elicited with limited Env protein
boosts in hosts primed with Env-expressing DNA vaccines
(Barnett et al., 1997; Cherpelis et al., 2001b; Leung et al., 2004;
Richmond et al., 1997). In the current study, a similar DNA
prime and Env protein boost vaccination regimen was evaluated
in the nonhuman primate model as the first step to establish the
immunogenicity of this vaccination approach in delivering
polyvalent HIV formulations. Rhesus macaques were initially
immunized with DNA vaccines encoding env genes (gp120)
from multiple clades of HIV-1 of R5 phenotype. Results
presented here clearly demonstrate that boosting of DNA-
primed macaques with gp120 proteins was highly effective in
eliciting significantly high-titered anti-Env antibody responses
recognizing a wide range of primary Env antigens. The immune
sera neutralized T cell line adapted (TCLA) and primary HIV-1
isolates with a varying degree of efficiency. Mucosal challenge
of these immunized animals with an R5 SHIV isolate led to
complete protection in the majority of immunized animals and a
significant containment of plasma viremia in the remaining
immunized animals compared to naïve animals.
Results
Immunization schedule
The immunization regimen of this study, consisting of both
primary and secondary immunization phases, is shown in Fig. 1.
The polyvalent DNA vaccines encoded the env gene from four
primary HIV-1 isolates: 92US715.6 (clade B), Ba-L (clade B),
96ZM651 (clade C), and 93TH976.17 (clade E) and the gag
gene from a molecularly cloned virus NL4-3 (clade B). Three
animals (961L, 963L, 969L) received DNA vaccines by geneimals were immunized with polyvalent DNA by gene gun and the other three by
studies were challenged with SHIV-Ba-L by rectal route. Arrows indicate times
343R. Pal et al. / Virology 348 (2006) 341–353gun and three animals (971L, 974L, 975L) were immunized
with the same polyvalent DNA immunogens by ID route on
weeks 0, 6, 14, and 18. Animals were boosted with four
homologous gp120 proteins in QS-21 adjuvant by IM route on
weeks 24 and 32. After confirmation of both antibody and cell-
mediated immune responses from this primary immunization
regimen, a secondary phase of immunization was given with
DNA on week 110 and protein on weeks 115 and 132 to
evaluate the longevity of HIV-1-specific antibody responses in
immunized animals. In order to determine whether boosting
with Gag protein would enhance CMI response to HIV-1 Gag
antigen, animals were also immunized with HIV-1 (HXB2) Gag
p41 protein on week 58 (not shown in Fig. 1). Animals were
challenged with SHIV-Ba-L via rectal route on week 135. SevenFig. 2. Antibody titers to Env and Gag proteins in macaques immunized with polyval
titers in the serum of macaques vaccinated with DNA by either gene gun (closed sym
ELISA against gp120 protein from primary HIV-1 isolates 92US715.6 (clade B), Ba-L
Serum was collected 2 weeks after each immunization. Antibody titers are based on t
compared with the corresponding dilution of preimmune serum and are expressed a
immunized group.naïve macaques were also challenged with the same dose of
SHIV-Ba-L via rectal route.
Antibody response elicited by the DNA prime and protein boost
vaccine during primary immunization phase
Serum antibody titers to individual gp120 and p41 Gag
proteins were assayed by ELISA following four DNA and two
protein immunizations (Fig. 2). Antibody titers measured after
the first DNA immunization were very low (data not shown).
However, the titers against each gp120 increased steadily with
subsequent DNA immunizations (Fig. 2). Immunization of
DNA using gene gun consistently elicited nearly two logs
higher antibody titers against each of the four primary gp120ent DNA and gp120 proteins during the primary immunization phase. Antibody
bol) or ID route (open symbol) and gp120 proteins by IM route were assayed by
, 96ZM651 (clade C), and 93TH976.17 (clade E) or against HXB2 Gag protein.
he dilution of immune serum producing two times the optical density at 450 nm
s the mean antibody titer ± SEM from three macaques of either gene gun or ID
Table 1
Neutralization of HIV-1 isolates by sera from macaques immunized with
polyvalent DNA prime followed by protein boost
Animal MNa SHIVBa-L a SF162 b Ba-L b ADA 5768 b 0515 b
961L 41 23 63 80 0 0 0
963L 161 41 87 77 0 0 0
969L 48 24 81 16 0 10 0
971L 54 27 66 67 0 0 0
974L 474 78 93 89 0 4 0
975L 51 17 76 47 0 0 0
Immune serum was collected after four DNA and two protein immunizations.
All HIV-1 isolates are from Clade B.
a Values for MN are the reciprocal serum dilution at which 50% of MT-2
cells were protected from virus-induced killing as measured by neutral red
uptake. Values for SHIVBa-L are the dilution of sera inhibiting 50% of
344 R. Pal et al. / Virology 348 (2006) 341–353antigens (between 1:1000 and 1:10,000) as compared to the ID
route (between 1:10 and 1:100). This enhanced response was
observed against each gp120 protein (Fig. 2). Boosting of
DNA-primed animals with a single administration of polyvalent
gp120 proteins enhanced antibody titers markedly. The gene
gun group had a slightly higher titer than the ID group,
especially against three of the four gp120 proteins present in the
immunogens (Fig. 2). However, after two protein boosts, all the
animals had Env-specific antibody titers above 1:100,000, and
titers were comparable in all animals irrespective of the route of
DNA priming (Figs. 2A–D). Similarly, antibodies to Gag
protein were also detected after DNA administration, especially
in the gene gun immunized animals. Moreover, titers were
lower than anti-gp120 antibodies and declined slightly after theFig. 3. Neutralizing activity in the serum of rhesus macaques following DNA
prime/protein boost immunization. Sera were collected 2 weeks after four DNA
and two protein immunizations and tested for neutralization of HIV-1 isolates.
(A) Neutralization of SHIV-Ba-L was conducted with cell-free virus in U373
cells and of B715 (92US715.6) and Czm (96ZM651) by cell–cell transmission
assay as described in Materials and methods. Neutralization titers are expressed
as dilution of immune sera inhibiting 50% of viral infection ± SEM from six
immunized macaques. The minimum dilution of serum tested in each assay was
1:4. (B) Sera were tested for neutralization at a 1:5 dilution for inhibitory activity
against panels of HIV-1 isolates from clades A, B, C, and E by flow cytometric
assay as described in Materials and methods. Data are presented as the mean
percent inhibition of infection ± SEM from six immunized macaques.
infection.
b Values for Bal, SF162, ADA, 5768, 0515, and PVO (R5, clade B isolates)
are the percent reduction in p24 synthesis relative to the amount of p24
synthesized in the absence of test sample in human PBMC. Serum samples
were screened at a 1:6 dilution in triplicate.gp120 protein boost, as Gag protein was not administered to the
animals (Fig. 2).
In order to determine whether antibodies elicited by the
multivalent DNA prime/protein boost vaccine are functional,
sera collected 2 weeks after the fourth DNA immunization and
each protein boost were assayed for neutralization of a number
of HIV-1 isolates from multiple clades (Fig. 3). Different assays
were performed to examine multiple aspects of HIV-1
neutralization by the immune sera. These assays examined
neutralization of a number of HIV-1 isolates both homologous
and heterologous to the vaccine strains and were conducted
independently in different laboratories with cell-free virus.
Since HIV-1 also propagates via cell-to-cell transfer, we
examined neutralization of cell-to-cell transmission of virus
by syncytium assay. In this assay, we quantitated inhibition of
syncytium formation induced by coculturing HIV-1 infected
cells with uninfected target cells in the presence of immune sera.
Initially, we tested neutralization of three isolates (SHIV-Ba-L,
92US715.6, and 96ZM651) homologous to the vaccine.
Neutralization of 92US715.6 and 96ZM651 was examined by
cell–cell transmission assay, and neutralization of SHIV-Ba-L
was examined with cell-free virus in U373 cells. DNA
immunization elicited weak neutralizing activity in four out of
six animals against 92US715.6 and two out of six animals
against 96ZM651 but failed to elicit measurable neutralization
titers against SHIV-Ba-L at the lowest dilution of serum (1:4)
tested (Fig. 3A). However, sera after each protein boost
neutralized these isolates markedly with higher titers observed
after the second boost (Fig. 3A). Neutralization of several
heterologous primary isolates across HIV-1 subtypes A, B, C,
and E was also tested using these sera (Fig. 3B). As observed
with homologous isolates, none of the primary isolates were
neutralized after DNA immunization. However, a clade A
(DJ263) and a number of clade B isolates were neutralized after
the first protein boost, and the percent neutralization was
increased following the second protein boost (Fig. 3B). Since
two protein boosts were necessary to elicit neutralizing antibody
responses against a number of isolates, serum from each animal
Fig. 5. Antibody titers to Env protein in macaques immunized with polyvalent
DNA and gp120 protein during the secondary immunization phase. Antibody
titers in the serum of macaques immunized with DNA by either gene gun (closed
symbol) or ID (open symbol) and with gp120 proteins by IM route were assayed
by ELISA against Ba-L gp120 protein. Animals were rested from week 32
through week 110 and were subsequently reboosted with DNA and proteins.
Serum was collected 2 weeks after each immunization. Antibody titers were
calculated as described in Fig. 2 and are presented as mean antibody titer ± SEM
from three macaques of either gene gun or ID immunized group.
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number of HIV-1 clade B isolates, and the results are shown in
Table 1. Although HIV-1 MN and two primary isolates (Ba-L
and SF162) were neutralized by the most of the immune sera,
other isolates were not neutralized in this assay.
HIV-1 Gag-specific cellular immune responses in immunized
macaques
HIV-1 Gag antigen was included in the DNA vaccine phase
of this polyvalent DNA prime/protein boost vaccine since it has
been demonstrated that immunogens based on HIV-1 Gag alone
were able to control plasma viremia in challenged macaques
(Shiver et al., 2002). Inclusion of a Gag antigen as part of the
DNA priming would increase the breadth of immune responses
elicited by an Env-based DNA prime plus protein boost
strategy. It was of interest to determine whether Gag-specific
CMI response following DNA immunization would be elicited
in such a formulation without interference from Env DNA
vaccines. PBMC from immunized macaques were isolated at 2
weeks after the fourth DNA immunization, and the Gag-specific
T cells were measured by IFN-γ ELISPOT assay, using HIV-1
MN Gag peptide pools spanning the p55 protein (15-mers with
11 amino acid overlap, 12 peptides in each pool). As shown in
Fig. 4, two of three animals in each gene gun or ID group
exhibited positive responses against one or more of the ten Gag
peptide pools tested. These results demonstrated that the Gag
DNA vaccine induced specific T cell responses in the DNA
priming phase.
Although immunization with DNA plasmids elicited Gag
antibody response in the immunized macaques, such antibody
titers dropped markedly following gp120 protein boosts (Fig. 2).
In order to determine whether Gag-specific humoral and CMI
responses could be boosted following immunization with Gag
protein, animals were immunized with a single dose of HIV-1Fig. 4. Gag peptide-specific cellular immune responses after the fourth DNA
immunization. The numbers of IFN-γ spot-forming cells per 106 PBMC were
measured by ELISPOT assays. Macaques received NL4-3 Gag DNAvaccine as
part of the Env plus Gag DNAvaccine formulation either by a gene gun (animals
961L, 963L, and 969L) or by intradermal injection (animals 971L, 974L, and
975L). Each bar represents the number of spots against one Gag peptide pool.Gag protein in QS-21 adjuvant on week 58. The immunized
animals developed high anti-Gag antibody titers, which dropped
with time (data not shown). However, Gag-specific CMI
response was not boosted following protein immunization,
suggesting that animals were properly primed against Gag
antigen for humoral antibody following DNA immunization, but
recombinant protein, as an exogenous antigen, was not effective
in entering intracellular antigen presentation pathways to boost
stronger CMI in gag DNAvaccinated animals (data not shown).
Antibody response during the secondary immunization phase
It is expected that an effective prophylactic vaccine should
maintain high-titered antibodies in serum for combating new
infections. Alternatively, if decay in antibody titer is observed,
additional immunization with the vaccine should boost the titers
markedly. Hence, we wanted to determine whether the anti-Env
antibody levels would drop following a prolonged rest period
and whether such antibody response could be reboosted with
the same polyvalent DNA and protein immunizations. Since
DNA immunization was necessary to prime both humoral and
cellular immune responses in the primary immunization phase,
we included a DNA boost in the secondary phase of
immunization after a prolonged rest. After a 78-week rest
following the second Env protein boost (on week 32), animals
were re-immunized with DNA on week 110 and with proteins
on week 115 and 132. As shown in Fig. 5, anti-gp120 titers
decreased with time following the second protein boost on week
32. Immunization with a single DNA on week 110 and two
protein boosts on weeks 115 and 132 increased anti-gp120 titers
comparable to that observed during the primary immunization
phase with boosting of antibody responses was more evident
following protein immunizations. Given that the antibody titers
Fig. 6. Plasma viral RNA load in macaques following SHIV-Ba-L challenge.
Plasma viral RNA (copies/1 ml) load was determined by NASBA (Romano et
al., 2000). RNA loads of individual animals from naïve (A) and immunized (B)
groups are plotted at different days post-challenge. Mean RNA load of seven
naïve and two infected macaques of vaccinated groups are plotted with SEM
(C).
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phase of immunization, it is likely that additional priming with
DNA may not be necessary in the secondary phase of
immunization. These results clearly demonstrate that although
antibodies elicited by DNA priming and protein boosts decay as
expected, such levels could be brought back to the original level
with limited immunizations with Env DNA and protein
vaccines.
Protection efficacy after rectal challenge with SHIV-Ba-L
Since the immunogens used in this vaccine originated from
R5 HIV-1 isolates and such viruses are known to transmit via
mucosal surface, these immunized animals were challenged
rectally with the chimeric SHIV-Ba-L 3 weeks after the last
gp120 protein boost on week 135. SHIV-Ba-L is an R5 isolate
and was shown to transmit efficiently via mucosal route without
causing any decline in CD4+ T cell counts (Pal et al., 2003).
Plasma RNA loads of each animal over time of both immunized
and naïve group are shown in Fig. 6. All seven animals enrolled
in the naïve group were infected following rectal challenge with
plasma viremia reaching peak between days 14 and 21 and
eventually controlling below detectable level (Fig. 6A). Four of
the immunized animals (961L, 963L, 974L, and 975L) were
shown to have no detectable plasma viremia as evidenced from
the RNA load determined by the NASBA assay which has a
lower limit sensitivity of 500 copies per milliliter plasma. Two
animals (969L and 971L) were infected at peak levels lower than
the naïve animals (Fig. 6B). This reduction in virus load between
the immunized and the naïve controls is significant for peak
viremia (P b 0.0012) and for area under the viral RNA peak
(P b 0.0023). Area under the viral RNA peak was also
significant when gene gun and ID group were compared
individually to the naïve group (P b 0.0167). As shown in Fig.
6C, mean peak viremia of the two infected immunized animals
was also lower than that of the control group. Virus was isolated
from the PBMC of animals with detectable virus load by
coculturing with human PBMC and not from animals with
undetectable plasma viremia (data not shown). No drop in CD4+
T cell count was noted following challenge in either immunized
or control animals (data not shown).
The infectious status of each animal was also confirmed by
qualitative PCR detection of SIV proviral DNA from PBMC
harvested 120 days following challenge using primers specific
to the gag gene. Macaques with no detectable RNA in the
plasma were also negative for proviral DNA in PBMC, whereas
all the infected animals had detectable SIV proviral DNA (data
not shown). As expected, control β-globulin gene expression in
the PBMC of all animals tested was comparable (data not
shown).
Post-challenge immune response
Animals were monitored after challenge for humoral and
cellular immune responses to SHIV-Ba-L (Fig. 7). As
expected, all the immunized animals had high-titered anti-
gp120 antibodies on the day of challenge and the antibodytiters stabilized 3 weeks following challenge (data not shown).
Mean neutralization titers of sera from the protected and the
infected animal against SHIV-Ba-L on the day of challenge are
shown in Fig. 7A. It is clear that while protected animals had
higher neutralizing activity against SHIV-Ba-L compared to
infected animals on the day of challenge, the titers in infected
Fig. 7. Post-challenge immune response in challenged macaques. (A)
Neutralizing antibody titers of serum collected on the day of challenge (day
0) and at days 6, 14, 21, and 35 post-challenge were assayed against SHIV-Ba-L
in U373 cells and are defined as the dilution of serum blocking 80% of infection.
Neutralizing antibody titers of sera were expressed as mean neutralizing
antibody titers ± SEM from four protected (961L, 963L, 974L, and 975L), two
infected (969L and 971L) or from naïve animals. (B) IFN-γ specific ELISPOT
assays were conducted with PBMC from four protected, two infected or from
naïve macaques collected on the day of challenge and at multiple time points
post-challenge in the presence of pooled Ba-L gp120 peptide pools. Results are
expressed as mean number of Ba-L Env-specific spot forming cells per 106
PBMC ± SEM from four protected or two infected animals.
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expected, sera from the naïve controls had developed weak
neutralizing activity only on day 35 post-challenge against
SHIV-Ba-L (Fig. 7A). These immune sera collected on the day
of challenge and on week 8 after challenge had weak to no
neutralizing activity against multiple heterologous primary
HIV-1 isolates (data not shown). These results suggest that
although multivalent DNA prime/protein boost vaccine elicited
protective immune response in a number of animals against
homologous SHIV challenge, such vaccine regimen did not
elicit neutralizing antibody response to a broad range of
primary HIV-1 isolates.
In order to determine whether CMI response to HIV-1 Env
also played a role in controlling SHIV-Ba-L infection in
challenged animals, ELISPOT assays were conducted by
stimulating PBMC from challenged animals with Ba-L Env
peptide pool at different times post-challenge. As shown in Fig.7B, IFN-γ-specific ELISPOT response was observed in all
immunized animals both on the day of challenge and post-
challenge. However, no difference was noted between the four
protected and two infected animals at any time point. As
expected, weak ELISPOT response to Ba-L Env in naïve
animals was only observed on day 35 post-challenge (Fig. 7B).
HIV-1 Gag-specific CMI was not measured following challenge
since HIV-1 Gag DNA vaccine was not expected to contribute
to the protection against a SHIV challenge.
Discussion
Immunogenicity studies conducted here clearly demonstrate
that priming of rhesus macaques with DNA encoding env genes
from multiple clades of HIV-1 and boosting with the
homologous gp120 protein was well tolerated and elicited
strong antibody responses in the immunized host. The route of
administration was shown to affect antibody responses elicited
by the DNAvaccine, as DNA administered by gene gun elicited
stronger antibody responses compared to ID route. This finding
is consistent with previous studies demonstrating that particle
bombardment of DNA restricts the antigen to the epidermal
layer and biases the immune response towards Th2 responses
(Alvarez et al., 2005; Feltquate et al., 1997; Weiss et al., 2002).
Although higher antibody responses were observed in the gene
gun immunized group relative to the ID group, DNA
immunization successfully primed humoral responses in all
macaques efficiently. Boosting of DNA-primed animals with
gp120 proteins enhanced the antibody response markedly to a
comparable level in all animals irrespective of the route of DNA
administration. Our findings that protein-mediated boosting of
humoral responses is not dependent on the route of DNA
administration is noteworthy given that gene gun technology
may not be available for large-scale human use in the near
future, and conventional needle injection may be the method of
choice to deliver DNA vaccines, especially in developing
countries.
The immunogenicity of polyvalent vaccines may be
negatively influenced due to interference among diverse
antigens present in the vaccine. Although mixtures of DNA
vaccines have been shown to decrease in vivo protein
expression thereby reducing immunogenicty of the vaccine
(Kjerrstrom et al., 2001; Sedegah et al., 2004), other studies
have demonstrated lack of such interference in multiclade DNA
vaccines (Kong et al., 2003; Seaman et al., 2005). Our results
demonstrate that immunization with multivalent env DNA
vaccines effectively primed antibody response to each gp120
present in the vaccine. Further, priming of both Gag-specific
humoral and cellular immune responses was noted, although
gag DNA was administered with four env DNA. This suggests
that immune response to Gag antigen was not compromised in
the presence of Env antigen.
We demonstrate here that high-titered anti-gp120 antibodies
elicited by the DNA prime/protein boost vaccine regimen in
rhesus macaques were able to neutralize three homologous HIV-
1 isolates efficiently. It is to be noted that the sera harvested after
protein boost neutralized SHIV-Ba-L, neutralization of primary
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assay (Fig. 3). Although SHIV-Ba-L was isolated from the
PBMC of an infected macaque, the env gene of this virus was
shown to maintain significant homology compared to the
parental molecular clone (Pal et al., 2003). Such homogeneity of
the env may account for higher sensitivity of SHIV-Ba-L
compared to primary HIV-1Ba-L, which was propagated
exclusively in primary macrophages. We also observed that
sera from the majority of the immunized animals were able to
neutralize a few heterologous primary HIV-1 isolates mainly
from subtype B and even an isolate (DJ263) from subtype A,
although Env from clade Awas not present in the vaccine. It is
possible that the presence of Env antigen from two isolates of
subtype B may account for such preferential activity against
clade B isolates. Further, neutralization of clade A isolate
suggests that protein boost increased the breadth of immune
response against other clades not included in the vaccine.
Although some of the isolates included in the panel of clade B
viruses are known to be neutralization sensitive (MN, SF162,
SHIV-Ba-L), progressive increase in the neutralization of these
and other isolates (ADA, BA-L) with protein boosts clearly
suggest that this vaccine is capable of eliciting neutralizing
antibody. Obviously the neutralizing activity elicited by the
vaccine is not optimal especially against all primary HIV-1
isolates, and additional efforts are being directed in the selection
and design of more potent Env-based immunogens.
Our results demonstrate that the immune response elicited by
the multivalent DNA prime/protein boost vaccine was able to
protect macaques from rectal challenge with SHIV-Ba-L isolate.
This isolate encoding HIV-1 Ba-L env gene was shown to be
CCR5 tropic and transmits efficiently via mucosal route without
inducing any CD4 decline in the infected macaque (Pal et al.,
2003). It is to be noted that although the virus does not induce a
pathogenic outcome in the challenged animals, the transmission
characteristics of this R5 SHIV via mucosal route has similarity
to other R5 SHIV isolates. First, the plasma viral RNA load
observed following rectal challenge with SHIV-Ba-L at the
acute stage of infection in naive animals (Fig. 6A) is comparable
to that observed with R5 SHIV162P3 (Harouse et al., 1999).
Second, as observed with SHIV-Ba-L, plasma viral RNA load
in macaques challenged with SHIV162P3 isolates often drops
markedly after the set point and peripheral blood CD4+ T cells
are preserved in a majority of the infected animals (data not
shown). This polyvalent vaccine formulation was able to confer
protection in four out of six animals against SHIV-Ba-L and
significantly reduced plasma viremia in the two remaining
animals. The conclusion that these animals were negative for
SHIV infection was based on three separate experimental
results. First, the animals showed no evidence of plasma viremia
at any of the time points measured. NASBA assay used for
RNA quantitation in plasma has a lower limit sensitivity of 500
copies per milliliter, and these four macaques had RNA loads
less than 500 copies per milliliter at all time points. Second,
virus could not be isolated by coculturing PBMC from these
macaques with human PBMC although such isolation was
readily achieved from PBMC of naïve animals and from two
infected animals of the immunized group. Third, there was noevidence of proviral DNA in the PBMC of these animals as
determined by qualitative PCR assay using gag gene-specific
primers, whereas all the infected animals were positive for
proviral DNA. While it is possible that the sensitivity of the
NASBA assay used here may have precluded detection of low-
level infection in these animals, given the other lines of
evidence of protection in these four animals, we do not believe
this to be the case. This efficacy against homologous challenge
is significant in light of the fact that the protection was observed
against mucosal transmission with a polyvalent vaccine, which
elicits broader immune response compared to a monovalent
vaccine. However, protection observed here against the
homologous challenge precludes complete evaluation of the
protective efficacy of the vaccine especially against heterolo-
gous challenge. Although the plasma viremia observed during
the acute phase of infection following rectal challenge with
SHIVBa-L is comparable to other R5 SHIV challenges, there
are a few limitations regarding this challenge model. One such
limitation is the lack of pathogenesis (i.e., no significant decline
in CD4 counts in blood and lack of persistence level of high
viremia in the chronic phase of infection) observed with this
challenge. To address these limitations and extend our findings,
future studies will use heterologous virus challenge with SHIV
isolates, which have been shown to be more pathogenic in
macaques. Partial efficacy of Env subunit-based vaccine has
been noted in other studies against homologous challenge.
Although live vector prime and subunit protein boost vaccines
did not confer sterilizing protection in rhesus macaques against
intravenous challenge with both nonpathogenic and pathogenic
homologous SHIV isolates, such vaccines reduced plasma
viremia compared to the control group (Earl et al., 2002).
Further, partial protection from homologous challenge was also
noted in macaques immunized with DNA encoding SHIV-
SF162ΔV2 Env and such protection was long term (Buckner et
al., 2004; Cherpelis et al., 2001a, 2001b).
In order to determine the immune correlates contributing to
the efficacy of this vaccine, we assayed neutralizing antibody
responses directed to the challenge virus on the day of challenge
and up to 5 weeks post-challenge. There was an inverse
correlation between the neutralizing activity against the
challenge virus and plasma virus load in these animals. Protected
animals with no detectable viremia had high neutralizing activity
on the day of challenge against the challenge virus, whereas the
two infected animals had low neutralizing activity. Interestingly,
with time, these two infected animals also developed high-
titered neutralizing activity to SHIV-Ba-L and such increase
appeared to control plasma viremia rapidly after 3 weeks post-
challenge compared to naïve animals. It has recently been
demonstrated that CMI response to Env may also play a role in
the containment of viral load in challenged animals (Letvin et al.,
2004). Since many of the animals had measurable levels of CMI
response to Ba-L Env at the time of challenge, we cannot rule out
the possibility that such responses might play a role for
containment of viral replication in these animals. It is possible
that this challenge outcome was determined by the anti-Env
immune responses and not by the SIV Gag antigen since the
macaques were immunized with HIV-1 Gag and not with SIV
Table 2













92US715.6 B USA CCR5 U08451
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gp120-E 93TH976.17 EA Thailand CCR5 U08458
Gag NL4-3 B USA N/A AF324493
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(pNL4-3) and SIVmac239 revealed 53% homology between
the two proteins with partial conservation of a few known CTL
epitopes (data not shown). Although not tested, CMI responses
elicited by such conserved CTL epitopes for the containment of
virus may not be overlooked. Since naïve animals immunized
with QS-21 alone were not included in this study as sham
controls, it is possible that the CMI responses noted here may,
in-part. be due to adjuvant alone. Although such nonspecific
CMI responses were not detected throughout this study, the use
of adjuvant-immunized animals as sham controls will be
included in future studies.
The genetic variation of HIV-1 represents a major obstacle in
the development of an effective vaccine against AIDS.
Although recently completed phase III clinical trials with
recombinant Env proteins have failed to demonstrate protective
efficacy against HIV-1 infection (Gilbert et al., 2005), it is
expected that multiple viral proteins from different clades will
maximize the breadth and potency of anti-HIV-1 immune
response, presumably due to the presentation of multiple anti-
viral epitopes. A polyvalent Env glycoprotein-based vaccine,
primarily with clade B Env of both primary and TCLA strains,
elicited a broader antibody response but failed to protect
animals from heterologous SHIV challenge (Cho et al., 2001).
The present study demonstrates that polyvalent vaccine
comprised of Env from multiple clades and delivered by
DNA prime and protein boost is immunogenic in rhesus
macaques and elicits neutralizing antibody response to HIV-1.
This antibody response was able to confer protection against
homologous challenge with an R5 SHIV isolate via mucosal
route in several immunized animals. Proper selection of env
genes representing specific immunotypes as well as modifica-
tion of Env proteins may improve the anti-HIV-1 immune
response elicited by the vaccines tested in this protocol, and
such responses may exhibit benefit as prophylactic vaccine in a
population where a number of diverse HIV-1 isolates are
present. Hence, this type of vaccine regimen needs to be
included in future vaccine development efforts.
Materials and methods
DNA vaccines
The HIV-1 Env and Gag immunogens are listed in Table 2.
HIV-1 env genes coding for subtypes B (B715), C, and E were
received from Drs. Feng Gao and Beatrice Hahn (University of
Alabama, Birmingham), whereas the env gene coding for Ba-L
was received from Dr. Marvin Reitz (Institute of Human
Virology, Baltimore). The gag gene used in Gag DNA vaccine
expressing Gag p55 antigen was derived from the HIV-1
infectious clone pNL4-3 (Adachi et al., 1986) (NIH AIDS
Research and Reference Reagent Program). The HIV-1 gag gene
and gp120 gene inserts coding for the above primary gp120
antigens were first PCR amplified by using the high fidelity PFU
polymerase (Strategene, CA) and individually subcloned in the
DNA vaccine vector pSW3891. All the DNA vaccines used in
the study were constructed using the same vector pSW3891. ThepSW3891 was derived from pJW4303 (Lu et al., 1999), but the
SV40 origin sequence was deleted, and the ampicillin resistance
gene was replaced with the Kanamycin resistance gene. The
pSW3891 contained cytomegalovirus (CMV) immediate early
(IE) promoter and its associated Intron A sequence. The HIV-1
gag or env gp120 inserts were in framewith a tissue plasminogen
activator (tPA) leader sequence. The plasmid DNAs for both Env
and Gag DNA vaccines were prepared commercially (Althea
Inc., CA) and were shown to contain N90% super coil structure
with low levels of endotoxin (b20 EU/mg). Each plasmid was
shown to be biologically active by measuring the transient
expression of either gp120 or p55 Gag protein in 293T cells
following transfection (data not shown).
Protein vaccines
Recombinant HIV-1 gp120 proteins were produced in either
293 or CHO cells stably transfected with gp120 expression
plasmids. Each codon-optimized gp120 gene was inserted into
the expression plasmids in-frame with the tPA signal peptide to
facilitate efficient secretion of the gp120 proteins into the
media. These plasmids contained the neomycin phosphotrans-
ferase II (nptII) and the mouse dihydrofolate reductase (dhfr)
genes for selection of stable colonies following transfection.
Both 293 and CHO dhfr- cells were transfected with the gp120
expression plasmids using lipofection. Stable cell lines
secreting gp120 were selected in the presence of the drug
Geneticin (G418 Sulfate). CHO cultures were further selected in
the presence of increasing levels of Methotrexate to enhance
gp120 production. Both 293 and CHO cultures were cloned by
limiting dilution and adapted for growth in serum and protein-
free media, respectively. The gp120 proteins were purified from
the conditioned media using Galanthus nivalis lectin agarose.
Proteins were formulated with QS-21 adjuvant, which was
received from Antigenics Inc. (Woburn, MA). HIV-1 (HXB2)
Gag protein (p41) containing domains of both p17 and p24
proteins was expressed as a fusion protein with a poly histidine
tag in E. coli using pET23 vector (Novagen, Madison, WI) and
purified from the cell lysate by nickel column chromatography
and reversed phase HPLC.
Animal studies
Indian rhesus macaques (Macaca mulatta) weighing 4–5 kg
were enrolled in the study. Macaques were immunized with
350 R. Pal et al. / Virology 348 (2006) 341–353DNA vaccines either by a gene gun or by needle injection
intradermally (ID). Each DNAwas administered separately. For
gene gun administration, 20 μg of each DNA was used per
immunization, whereas 500 μg of each DNAwas administered
by ID route, both at weeks 0, 6, 14, 18, and 110. For gene gun
delivery, individual Gag or gp120 DNA plasmids were coated
onto the 1.0-μm gold beads at a ratio of 5 μg of DNA per
milligram of gold, and each gene gun shot delivered 5 μg of
DNA. For each immunization, a total of 20 nonoverlapping
shots were delivered onto shaved abdominal skin using Bio-Rad
Helios gene gun (Bio-Rad, Hercules, CA). For ID delivery, each
DNA immunization was administered at two sites (250 μg per
site) in abdominal skin. Animals were boosted intramuscularly
with purified recombinant gp120 protein (75 μg per gp120
protein) formulated with 100 μg of QS-21 at weeks 24, 32, 115,
and 132. Proteins were pooled prior to immunization. Animals
were also immunized with a single dose of Gag (p41) protein
(75 μg) in 100 μg QS-21 on week 58. The immunized and naïve
animals were challenged rectally on week 135 with SHIV-Ba-L
(2000 TCID50/ml). Niave animals were nonsham-vaccinated
animals. The SHIV-Ba-L challenge stock was prepared by
culturing phytohemagglutinin (PHA)-activated peripheral
blood mononuclear cells (PBMC) from a SHIV-Ba-L infected
pigtail macaque (Pal et al., 2003). Each animal was inoculated
with 1 ml of undiluted virus (2000 TCID50) stock rectally since
this dose of virus consistently infected naïve animals in separate
titration studies.
Binding antibody assay
Serum samples were tested for Env gp120 and Gag-
specific antibodies using an enzyme-linked immunoabsorbent
assay (ELISA) as described before (Pal et al., 2002). Briefly,
polystyrene plates (Greiner Bio-one, Longwood, FL) were
coated with gp120 or Gag p41 protein (50 ng/well) in 100 μl
phosphate buffer (pH 7.2) at 4 °C overnight. The solution was
aspirated, and the wells were washed with wash buffer (PBS
containing 0.5% Tween 20) four times, and each well was
treated with 200 μl of blocking buffer (water containing 2.5%
BSA and 1.25% dry milk) for 1 h at 37 °C. After washing
with wash buffer, 100 μl of serum serially diluted in Dilsim II
(bioMerieux, Inc., Durham, NC) was added to each well and
incubated for 1 h at 37 °C. Plates were again washed with
wash buffer, and each well was incubated for 1 h at 37 °C
with 100 μl of 1:5000 dilution of goat anti-human HRP
labeled IgG (KPL Labs, Gaithersburg, MD) in conjugate
buffer (PBS containing 10% normal goat serum, 0.1% Tween
20 and 0.2% BSA). Plates were then thoroughly washed with
wash buffer, and each well was reacted with 100 μl of
Enhanced K-Blue Substrate (Neogen, Lexington, KY) at
room temperature for 30 min. Reaction was terminated by
adding 100 μl of 2N H2SO4 to each well, and the optical
density was read in an ELISA plate reader at 450 nm.
Antibody titers were defined as the highest dilution of
immune serum yielding optical density greater than two times
the optical density detected with a corresponding dilution of
preimmune serum.Neutralization assays
Different types of neutralization assays were conducted with
cell-free virus to measure neutralizing activity of the immune
serum. Neutralization assay of SHIV-Ba-L was performed in
U373 cells, which express a reporter gene β-galactosidase under
HIV-1 LTR promoter. Different dilutions of immune serum were
incubated with 200 TCID50 of SHIV-Ba-L for 60 min at 37 °C.
Serum-virus mixture was then added to U373 cells coated onto
96-well plates and incubated for 48 h. Cells were thoroughly
washed, and fresh medium was added to each well. Expression
of β-galactosidase was measured as chemiluminescence output
after 96 h to monitor viral infection using Galacto-Start One-
Step Galactosidase Reporter Gene Assay System (Applied
Biosystems, Foster City, CA). Neutralization assay based on
intracellular p24-Ag (HIV-1 Gag p24 antigen) staining was
conducted in 96-well U-bottom culture plates and measured by
flow cytometric analysis as previously described (Mascola et al.,
2002). Neutralization of HIV-1MN was assayed in MT2 cells,
whereas neutralization of several other primary isolates was also
assayed in human PBMC as described before (Crawford et al.,
1999). Additional neutralization assays were conducted in TZM-
bl cells (NIH AIDS Research and Reference Reagent Program,
contributed by John Kappes and Xiaoyun Wu) with pseudo
viruses as described elsewhere (Montefiori, 2004). Briefly, 200
TCID50 of virus was incubated with 1:20 dilutions of serum
samples in triplicate in a total volume of 150 μl for 1 h at 37 °C in
96-well flat-bottom culture plates. Freshly trypsinized cells
(10,000 cells in 100 μl of growth medium containing 75 μg/ml
DEAE dextran) were added to each well. One set of control wells
received cells plus virus (virus control), and another set received
cells only (background control). After a 48-h incubation, 100 μl
of cells was transferred to 96-well black solid plates for
measurements of luminescence using Bright Glo substrate
solution as described by the supplier (Promega, Madison, WI).
Assay stocks of gp160-pseudotyped viruses were prepared by
transfection in 293T cells and titrated in TZM-bl cells.
Neutralization of cell-to-cell transmission was measured by
coculturing uninfected CEM cells expressing CCR5 (CEM-
CCR5) with either chronically HIV-1 infected CEM-CCR5 or
PM1 cells in the presence of the immune serum. Syncytia were
scored after 72 h, and the dilutions of serum inhibiting 50% of
syncytia were defined as the syncytium blocking titer.
ELISPOT assay
96-well PVDF-bottomed plates (Millipore, Billerica, MA)
were pretreated with 70% ethanol and air dried for 15 min.
Plates were washed four times with PBS and then coated with 5
μg/ml of mouse anti-human IFNγ capture antibody (BD
Pharmingen, San Diego, CA) in PBS and incubated overnight
at 4 °C. Following incubation, plates were washed five times
with complete RPMI media (RPMI1640 supplemented with
10% fetal bovine serum, 2 mM L-glutamine and 100 μg/ml each
of penicillin and streptomycin). Rhesus PBMC (2.0 × 105 cells/
well) were then added to the wells in 100 μl of complete RPMI
and were stimulated with either HIV-1 Env or Gag peptides for
351R. Pal et al. / Virology 348 (2006) 341–35318 h. Care was taken to ensure that final DMSO concentrations
did not exceed 0.5%. Following incubation for 18 h at 37 °C in a
CO2 incubator, plates were washed five times with PBS con-
taining 0.05% Tween 20. Biotinylated anti-IFNγ (Diapharma,
West Chester, OH), diluted with PBS containing 2% fetal
bovine serum, 0.05% Tween 20, and 1% BSA, was added to
wells at a final concentration of 1 μg/ml. Plates were incubated
at 37 °C for 2 h and then washed five times with PBS containing
0.5% Tween 20. Avidin–HRP (Vector Laboratories, Burlin-
game, CA) was diluted in PBS containing 2% FBS, 1% BSA,
0.05% Tween 20, and added to wells at a final dilution of
1:2000. Plates were incubated for 1 h at 37 °C. Following
incubation, plates were washed five times with wash buffer, and
100 μl of Stable DAB substrate (Research Genetics, Huntsville,
AL) was added to each well. Spots were visualized within 3 to 5
min, and the reaction was terminated by washing plates
thoroughly with water. Plates were dried overnight, spots
were counted using the VWR Vista Vision Stereo Zoom
Microscope (VWR, West Chester, PA).
Virological assays to monitor challenge outcome
Animals were bled periodically following challenge, and
viral load in plasma was assessed using a more sensitive nucleic
acid sequence-based amplification assay (NASBA) to quanti-
tate SIV RNA (Romano et al., 2000). This assay has a lower
limit sensitivity of 500 copies of SIV RNA per milliliter of
plasma. To confirm virus transmission, PBMC collected from
animals 21 days following virus challenge were subjected to
qualitative virus isolation by coculturing with PHA-activated
human PBMC (Pal et al., 2002). In addition, qualitative PCR
assays were conducted for the detection of proviral DNA in the
PBMC of challenged animals. DNA was isolated from PBMC
with Qiagen's QIAmp DNA blood kit (Qiagen, Valencia, CA)
using the manufacturer's protocol, and the DNAwas amplified
with primers specific to the gag gene of SIV using standard
conditions of amplification. Amplified product was detected by
agarose gel electrophoresis. Amplification of the β-globulin
gene served as positive amplification control in each assay.
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